Blueberry compound pterostilbene helps muscle cells burn stored fat

Excess fat accumulating inside skeletal muscle — a condition called myosteatosis — is increasingly recognized as a driver of metabolic dysfunction in aging. Unlike subcutaneous fat, intramuscular lipid droplets interfere directly with glucose and fatty acid utilization, contributing to insulin resistance and reduced metabolic flexibility over time. Finding dietary compounds that can address this specific problem has been a research priority, and a new study from Japan points to pterostilbene as a promising candidate.

Scientists at Shinshu University, led by Associate Professor Takakazu Mitani, screened a library of food-derived phytochemicals using cultured C2C12 mouse skeletal muscle cells loaded with excess lipids. Among all compounds tested, pterostilbene — a polyphenol naturally present in blueberries, grapes, and other berries — produced the most potent reduction in intracellular fat accumulation without impairing normal muscle cell growth or differentiation.

Critically, the mechanism did not involve blocking fatty acid entry into the cells. Instead, treated cells released more glycerol into the surrounding medium — a direct indicator of fat breakdown — and showed elevated expression of genes governing fatty acid oxidation. The team traced this activity upstream to PPAR-delta, a nuclear receptor that, when active, promotes lipid burning. Pterostilbene appeared to stabilize PPAR-delta protein, keeping the fat-burning pathway switched on more reliably.

The practical implication is significant: a widely available dietary compound may help muscle tissue maintain metabolic flexibility, particularly relevant as aging and inactivity push intramuscular fat higher. Pterostilbene has previously shown metabolic benefits in liver and adipose tissue; this work extends its mechanism to skeletal muscle, the body's largest site of glucose disposal.

Important caveats apply. All experiments were conducted in mouse-derived cell cultures, meaning the dose, bioavailability, and efficacy in living humans remain unknown. No clinical trials have yet tested pterostilbene specifically for myosteatosis. The findings, published in Food Bioscience, are mechanistically informative but require validation in animal models and ultimately human studies before any therapeutic conclusions can be drawn.